On February 10, 2025, Bio-Thera Solutions, Ltd. announced that they entered into an exclusive licensing agreement with Intas Pharmaceuticals Ltd. to commercialize BAT2506 (golimumab), Bio-Thera ...

Credit: sergey kolesnikov/Shutterstock. Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for the Simponi (golimumab) biosimilar, BAT2506 ...

RALEIGH, N.C., Feb. 10, 2025 /PRNewswire/ — Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. (“Intas Pharmaceuticals ...

This marks the first U.S. BLA acceptance for a golimumab biosimilar, an anti-TNF therapy for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The FDA review is expected to ...

These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth ...

These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth quarter of ...

Discover comprehensive details about Golimumab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

This medication is a tumor necrosis factor (TNF) blocker, prescribed for rheumatoid arthritis, ankylosing spondylitis, moderate to severe ulcerative colitis either alone or with other medications.

Alvotech’s proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. This is believed to be the first marketing authorization application ...

High Wycombe, UK, 17 October 2024 - Johnson & Johnson (J&J) announced today that it has now assumed all sales, marketing and distribution responsibility for Remicade® (infliximab) and Simponi® ...